SunWay Biotech (1271.TW) reported robust financial results for the first half of 2026, with consolidated revenue reaching NT$1.01 billion ($31.2 million), a 116.7% increase year-over-year. Net profit after tax rose 79.8% to NT$79.28 million ($2.5 million), and earnings per share increased nearly 70% to NT$1.24. The company attributes its growth to the acquisition of the international sports nutrition brand WGN and strong export performance, particularly in Europe, where demand for its patented red yeast rice ingredient has surged. Despite a decline in operating profit due to one-time costs from the WGN acquisition, SunWay expects further growth driven by improved sales strategies and a strong market demand for health and sports nutrition products. The full consolidation of WGN’s revenue in Q3 is anticipated to enhance operational performance in the latter half of the year.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.biggo.com/news/a9aa94cd-7fa4-4820-84a4-21159230ab4a
